Search Log In

Volume

Drug resistance and combating drug resistance in cancer

Emerging targets in cancer drug resistance

Mechanism of resistance to immune checkpoint inhibitors

Molecular mechanisms of enzalutamide resistance in prostate cancer

New insights into acquired endocrine resistance of breast cancer

Overcome cancer drug resistance by targeting epigenetic modifications of centrosome

Pharmacogenetic and pharmacogenomic discovery strategies

Pharmacogenetics of asparaginase in acute lymphoblastic leukemia

Pharmacogenetics of thiopurines

Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients

Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer

The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities

The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors

Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation

Perspective: plasticity, the enemy of the good

Glutaminase inhibition in renal cell carcinoma therapy

Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction

Actions for 0 selected articles

Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/
partners@oaepublish.com Company Contact Us
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
© 2016-2024 OAE Publishing Inc., except certain content provided by third parties